IMMP
Immutep Limited
NASDAQ · Healthcare · Biotechnology · AU
$0.36
−0.05%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 21.7M | 14.2M | 5.0M | 3.8M | 3.5M |
| Cost of Revenue | 109.1M | 2.4M | 61.4M | 41.5M | 2.1M |
| Gross Profit | (87.4M) | 11.8M | (56.4M) | (37.7M) | 1.4M |
| Operating Expenses | |||||
| R&D Expense | 61.4M | 75.0M | 61.4M | 41.5M | 28.8M |
| SG&A Expense | 63.2M | 18.9M | 8.6M | 8.9M | 14.1M |
| General & Admin Expense | 14.1M | — | 8.6M | 8.9M | 8.7M |
| Selling & Marketing Expense | — | — | — | — | 5.4M |
| Other Expenses | — | — | — | — | 2.1M |
| Total Operating Expenses | 124.6M | 93.9M | 70.1M | 50.4M | 44.9M |
| Cost and Expenses | 233.7M | 96.3M | 131.5M | 91.9M | 81.2M |
| Operating Income (EBIT) | (212.0M) | (82.0M) | (126.4M) | (88.1M) | (77.7M) |
| Non-Operating | |||||
| Interest Income | 8.2M | 2.9M | 5.3M | 3.9M | 939.0K |
| Interest Expense | 68.2K | 66.4K | — | 30.6K | 20.4K |
| Net Interest Income | 8.2M | 2.9M | 5.3M | 3.9M | 918.6K |
| Other Non-Op Income/Expense | 70.8M | 4.5M | 65.0M | 45.4M | 37.8M |
| Non-Operating Income (excl Interest) | (61.4M) | — | (61.4M) | (41.5M) | (36.3M) |
| EBT (Pre-Tax Income) | (141.2M) | (77.6M) | (61.4M) | (42.7M) | (39.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (141.2M) | (77.6M) | (61.4M) | (42.7M) | (39.9M) |
| Earnings from Cont. Ops | (141.2M) | (77.6M) | (61.4M) | (42.7M) | (39.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (141.2M) | (77.6M) | (61.4M) | (42.7M) | (39.9M) |
| Per Share | |||||
| Basic EPS | ($0.95) | ($0.53) | ($0.42) | ($0.36) | ($0.44) |
| Diluted EPS | ($0.95) | ($0.53) | ($0.42) | ($0.36) | ($0.44) |
| Revenue Per Share | $0.15 | $0.10 | $0.03 | $0.03 | $0.04 |
| Shares | |||||
| Basic Shares Outstanding | 147.4M | 147.2M | 145.6M | 120.0M | 90.1M |
| Diluted Shares Outstanding | 147.4M | 147.2M | 145.6M | 120.1M | 90.1M |
| Profitability Metrics | |||||
| EBITDA | (146.2M) | (79.6M) | (62.9M) | (44.5M) | (39.6M) |
| D&A | 4.3M | 2.4M | 2.1M | 2.0M | 1.9M |
| EBIT | (150.6M) | (82.0M) | (65.0M) | (46.6M) | (41.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026